|
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
|
25111384 |
2014 |
|
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Resistance of malignant gliomas to TMZ can be overcome by synchronizing metronomic TMZ regimen with MGMT expression.
|
21892781 |
2012 |
|
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that dexamethasone-mediated upregulation of MGMT limits the efficiency of alkylating agents in the treatment of malignant gliomas.
|
15481722 |
2004 |
|
Malignant Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lack of MGMT protein expression immunohistochemically is related to drug responses in patients with malignant glioma treated with alkylating agents.
|
24374955 |
2013 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
|
27158275 |
2016 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results.
|
29882028 |
2018 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation in malignant gliomas.
|
20725792 |
2010 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide.
|
22614944 |
2012 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
|
19997073 |
2010 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant methylation of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene is a predictive marker for the response to chemotherapy with alkylating agents (e.g., temozolomide) in malignant gliomas.
|
18795231 |
2009 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The MGMT promoter methylation status of malignant gliomas can be reliably determined from small-sized stereotactic biopsies.
|
17691113 |
2007 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We investigated the impact of MGMT methylation and expression on survival of children with high-grade glioma (HGG) registered into the German HIT-GBM database receiving temozolomide (TMZ) as part of their treatment (n = 21 relapsed, n = 4 primary).
|
19856394 |
2010 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
|
21365007 |
2011 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
|
19335893 |
2009 |
|
Malignant Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The study purpose was to investigate the non-invasive predictability of IDH mutation status, MGMT promoter methylation, and differentiation of low-grade versus high-grade glioma (LGG vs HGG) in newly diagnosed patients employing relaxation-compensated multipool chemical exchange saturation transfer (CEST) MRI at 7.0 Tesla.
|
29733378 |
2018 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently published results of trials on elderly patients with malignant gliomas have revived the call for routine MGMT testing for clinical decision making.
|
23083460 |
2013 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
|
16033832 |
2005 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The DNA repair enzyme O(6)-methylguanine DNA methyltransferase (MGMT) may cause resistance to DNA-alkylating drugs commonly used in the treatment of anaplastic oligodendrogliomas and other malignant gliomas.
|
15455350 |
2005 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
|
19901110 |
2009 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study identified clinicopathological factors related to postoperative seizure in HGGs and found two predictive biomarkers of postoperative seizure: MGMT and EGFR.
|
26808114 |
2016 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
|
16899598 |
2006 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
According to pathological examination, the tumor was a high-grade glioma that was positive for methylated O-6-methylguanine-DNA methyltransferase promoter.
|
20354758 |
2010 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) removes mutagenic adducts from the O6 position of guanine, thereby protecting the genome against guanine : cytosine to adenine : thymine transition and, meanwhile, conferring tumor resistance to many anti-cancer alkylating agents commonly used in the treatment of malignant gliomas.
|
14570288 |
2003 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that, in pHGG, (a) MGMT promoter methylation is less frequent than in adult malignant gliomas, (b) there is a high correlation between MGMT MSP and MGMT IHC, and (c) as in adults, MGMT status is associated with prognosis, although this observation has to be statistically validated on larger series of patients.
|
20552207 |
2010 |
|
Malignant Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As such, MGMT is gaining increasing traction in diagnosis, prognostication, and therapeutic decision-making for these highly malignant gliomas.
|
30444735 |
2019 |